Cyclerion Therapeutics (CYCN) Non-Current Assets (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Non-Current Assets of $5.4 million for Q4 2025, little changed year-over-year from $5.4 million in Q4 2024, and little changed quarter-over-quarter from $5.4 million in Q3 2025.
Cyclerion Therapeutics (CYCN) Non-Current Assets (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Non-Current Assets history runs 8 years deep, the most recent figure standing at $5.4 million for Q4 2025.
- In Q4 2025, Non-Current Assets changed 0.0% year-over-year to $5.4 million; the TTM figure through Dec 2025 stood at $21.4 million (changed 0.0% YoY), while the FY2025 annual figure was $5.4 million, changed 0.0% from the prior year.
- Non-Current Assets for Q4 2025 stood at $5.4 million, roughly flat from $5.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $55.5 million in Q1 2021, with the low at $2.7 million in Q2 2021.
- The 5-year median for Non-Current Assets is $5.4 million (2023), against an average of $7.0 million.
- The sharpest annual moves came in 2021 and 2024: Non-Current Assets tumbled 95.99% in 2021, then jumped 79.29% in 2024.
- Cyclerion Therapeutics' Non-Current Assets stood at $3.9 million in 2021, then declined by 15.88% to $3.3 million in 2022, then jumped by 64.16% to $5.4 million in 2023, then changed by 0.0% to $5.4 million in 2024, then changed by 0.0% to $5.4 million in 2025.
- Business Quant data shows CYCN's Non-Current Assets at $5.4 million in Q4 2025, $5.4 million in Q3 2025, and $5.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | 5.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.35 Mn |
| Sep 30, 2025 | 5.35 Mn |
| Jun 30, 2025 | 5.35 Mn |
| Mar 31, 2025 | 5.35 Mn |
| Dec 31, 2024 | 5.35 Mn |
| Sep 30, 2024 | 5.35 Mn |
| Jun 30, 2024 | 5.35 Mn |
| Mar 31, 2024 | 5.35 Mn |
| Dec 31, 2023 | 5.35 Mn |
| Sep 30, 2023 | 5.35 Mn |
| Jun 30, 2023 | 2.98 Mn |
| Mar 31, 2023 | 3.12 Mn |
| Dec 31, 2022 | 3.26 Mn |
| Sep 30, 2022 | 3.40 Mn |
| Jun 30, 2022 | 3.53 Mn |
| Mar 31, 2022 | 3.69 Mn |
| Dec 31, 2021 | 3.87 Mn |
| Sep 30, 2021 | 4.06 Mn |
| Jun 30, 2021 | 2.74 Mn |
| Mar 31, 2021 | 55.52 Mn |